1. Home
  2. RVMD vs GGAL Comparison

RVMD vs GGAL Comparison

Compare RVMD & GGAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RVMD
  • GGAL
  • Stock Information
  • Founded
  • RVMD 2014
  • GGAL 1905
  • Country
  • RVMD United States
  • GGAL Argentina
  • Employees
  • RVMD N/A
  • GGAL N/A
  • Industry
  • RVMD Biotechnology: Biological Products (No Diagnostic Substances)
  • GGAL Commercial Banks
  • Sector
  • RVMD Health Care
  • GGAL Finance
  • Exchange
  • RVMD Nasdaq
  • GGAL Nasdaq
  • Market Cap
  • RVMD 8.7B
  • GGAL 9.2B
  • IPO Year
  • RVMD 2020
  • GGAL N/A
  • Fundamental
  • Price
  • RVMD $44.06
  • GGAL $63.59
  • Analyst Decision
  • RVMD Strong Buy
  • GGAL Strong Buy
  • Analyst Count
  • RVMD 12
  • GGAL 4
  • Target Price
  • RVMD $64.67
  • GGAL $59.00
  • AVG Volume (30 Days)
  • RVMD 2.2M
  • GGAL 1.3M
  • Earning Date
  • RVMD 11-06-2024
  • GGAL 01-03-2025
  • Dividend Yield
  • RVMD N/A
  • GGAL 3.73%
  • EPS Growth
  • RVMD N/A
  • GGAL 32.62
  • EPS
  • RVMD N/A
  • GGAL 0.56
  • Revenue
  • RVMD $742,000.00
  • GGAL $4,434,816,496.00
  • Revenue This Year
  • RVMD N/A
  • GGAL N/A
  • Revenue Next Year
  • RVMD $1,855.42
  • GGAL N/A
  • P/E Ratio
  • RVMD N/A
  • GGAL $12.95
  • Revenue Growth
  • RVMD N/A
  • GGAL N/A
  • 52 Week Low
  • RVMD $25.93
  • GGAL $15.32
  • 52 Week High
  • RVMD $62.40
  • GGAL $70.30
  • Technical
  • Relative Strength Index (RSI)
  • RVMD 32.07
  • GGAL 59.20
  • Support Level
  • RVMD $44.50
  • GGAL $56.74
  • Resistance Level
  • RVMD $46.15
  • GGAL $70.30
  • Average True Range (ATR)
  • RVMD 1.89
  • GGAL 3.51
  • MACD
  • RVMD -0.58
  • GGAL 0.16
  • Stochastic Oscillator
  • RVMD 19.95
  • GGAL 53.21

About RVMD Revolution Medicines Inc.

Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.

About GGAL Grupo Financiero Galicia S.A.

Grupo Financiero Galicia SA is a financial service holding company. It provides general banking services, proprietary brand credit card services, personal loans, insurance, and other services. The company's operating business segments are Banks, Ecosistema Naranja X, Insurance, Adjustments, and Other Businesses. It generates maximum revenue from Banks. Geographically its operate in Argentina, Uruguay, and the majority of its revenue comes from Argentina.

Share on Social Networks: